ID

19065

Description

A Study of Pertuzumab in Participants With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02480010

Lien

https://clinicaltrials.gov/show/NCT02480010

Mots-clés

Versions (1)
  1. 02/12/2016 02/12/2016 -
Téléchargé le

2 décembre 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer DRKS00010313 NCT02480010

Anglais

Eligibility Prostate Cancer NCT02480010

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
adults greater than (>) 18 years of age
Description

Adult | Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001675
UMLS CUI [2]
C0001779
histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
Description

Adenocarcinoma of prostate Hormone Therapy Resistant | Androgen Antagonists Withdrawal | Disease Progression

Type de données

boolean

Alias
UMLS CUI [1,1]
C0007112
UMLS CUI [1,2]
C0279025
UMLS CUI [1,3]
C0332325
UMLS CUI [2,1]
C0002842
UMLS CUI [2,2]
C2349954
UMLS CUI [3]
C0242656
prostate-specific antigen (psa) values at least 20 ng/ml among those with asymptomatic or mildly symptomatic disease
Description

Prostate specific antigen measurement Asymptomatic Disease | Prostate specific antigen measurement Disease Symptomatic Mild

Type de données

boolean

Alias
UMLS CUI [1,1]
C0201544
UMLS CUI [1,2]
C2936329
UMLS CUI [2,1]
C0201544
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0231220
UMLS CUI [2,4]
C2945599
karnofsky performance status (kps) at least 80 percent (%)
Description

Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1]
C0206065
castrate testosterone less than (<) 50 ng/dl
Description

Castrated male Testosterone measurement

Type de données

boolean

Alias
UMLS CUI [1,1]
C1319065
UMLS CUI [1,2]
C0523912
life expectancy at least 12 weeks
Description

Life Expectancy

Type de données

boolean

Alias
UMLS CUI [1]
C0023671
left ventricular ejection fraction (lvef) at least 50%
Description

Left ventricular ejection fraction

Type de données

boolean

Alias
UMLS CUI [1]
C0428772
adequate hematologic, hepatic, and renal function
Description

Hematologic function | Liver function | Renal function

Type de données

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
Description

Chemotherapy Prostate carcinoma | Immunotherapy Prostate carcinoma

Type de données

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C0600139
UMLS CUI [2,1]
C0021083
UMLS CUI [2,2]
C0600139
systemic corticosteroids within 1 month prior to screening
Description

Adrenal Cortex Hormones Systemic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0205373
bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug
Description

Diphosphonates | Narcotic Analgesics | Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0012544
UMLS CUI [2]
C0027409
UMLS CUI [3]
C0013230
prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent
Description

Doxorubicin Cumulative Dose

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013089
UMLS CUI [1,2]
C2986497
central nervous system (cns) or pulmonary metastases
Description

CNS metastases | Secondary malignant neoplasm of lung

Type de données

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C0153676
other malignancies, except adequately treated basal or squamous cell skin cancer
Description

Malignant Neoplasms | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C0007117
UMLS CUI [2,2]
C1522326
UMLS CUI [3,1]
C0553723
UMLS CUI [3,2]
C1522326
significant cardiovascular disease
Description

Cardiovascular Disease Significant

Type de données

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0750502
active/uncontrolled concurrent illness or infection
Description

Comorbidity Uncontrolled | Communicable Disease Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0009450
UMLS CUI [2,2]
C0205318
major surgery or traumatic injury within 4 weeks of study drug
Description

major surgery | Traumatic injury

Type de données

boolean

Alias
UMLS CUI [1]
C0679637
UMLS CUI [2]
C3263723
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT02480010

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adult | Age
Item
adults greater than (>) 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Adenocarcinoma of prostate Hormone Therapy Resistant | Androgen Antagonists Withdrawal | Disease Progression
Item
histologically documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
boolean
C0007112 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0332325 (UMLS CUI [1,3])
C0002842 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
C0242656 (UMLS CUI [3])
Prostate specific antigen measurement Asymptomatic Disease | Prostate specific antigen measurement Disease Symptomatic Mild
Item
prostate-specific antigen (psa) values at least 20 ng/ml among those with asymptomatic or mildly symptomatic disease
boolean
C0201544 (UMLS CUI [1,1])
C2936329 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0231220 (UMLS CUI [2,3])
C2945599 (UMLS CUI [2,4])
Karnofsky Performance Status
Item
karnofsky performance status (kps) at least 80 percent (%)
boolean
C0206065 (UMLS CUI [1])
Castrated male Testosterone measurement
Item
castrate testosterone less than (<) 50 ng/dl
boolean
C1319065 (UMLS CUI [1,1])
C0523912 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy at least 12 weeks
boolean
C0023671 (UMLS CUI [1])
Left ventricular ejection fraction
Item
left ventricular ejection fraction (lvef) at least 50%
boolean
C0428772 (UMLS CUI [1])
Hematologic function | Liver function | Renal function
Item
adequate hematologic, hepatic, and renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Chemotherapy Prostate carcinoma | Immunotherapy Prostate carcinoma
Item
prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
boolean
C0392920 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
Adrenal Cortex Hormones Systemic
Item
systemic corticosteroids within 1 month prior to screening
boolean
C0001617 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Diphosphonates | Narcotic Analgesics | Investigational New Drugs
Item
bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any investigational agent with 28 days of study drug
boolean
C0012544 (UMLS CUI [1])
C0027409 (UMLS CUI [2])
C0013230 (UMLS CUI [3])
Doxorubicin Cumulative Dose
Item
prior cumulative doxorubicin dose of > 360 mg/m^2 or equivalent
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
CNS metastases | Secondary malignant neoplasm of lung
Item
central nervous system (cns) or pulmonary metastases
boolean
C0686377 (UMLS CUI [1])
C0153676 (UMLS CUI [2])
Malignant Neoplasms | Basal cell carcinoma Treated | Squamous cell carcinoma of skin Treated
Item
other malignancies, except adequately treated basal or squamous cell skin cancer
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0553723 (UMLS CUI [3,1])
C1522326 (UMLS CUI [3,2])
Cardiovascular Disease Significant
Item
significant cardiovascular disease
boolean
C0007222 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
Comorbidity Uncontrolled | Communicable Disease Uncontrolled
Item
active/uncontrolled concurrent illness or infection
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
major surgery | Traumatic injury
Item
major surgery or traumatic injury within 4 weeks of study drug
boolean
C0679637 (UMLS CUI [1])
C3263723 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial